MDGL Madrigal Pharmaceuticals Inc

$529.21

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 11/17/2025

About Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic and liver diseases. The company is headquartered in West Conshohocken, Pennsylvania.

Website: https://www.madrigalpharma.com

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1157601
Address
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA, US
Valuation
Market Cap
$6.66B
P/E Ratio
nan
PEG Ratio
0.00
Price to Book
8.83
Performance
EPS
$-21.90
Dividend Yield
—
Profit Margin
-258.60%
ROE
-80.30%
Technicals
50D MA
$330.50
200D MA
$289.57
52W High
$377.46
52W Low
$189.00
Fundamentals
Shares Outstanding
22M
Target Price
$414.07
Beta
-0.69

MDGL EPS Estimates vs Actual

● Estimated
● Actual

MDGL News & Sentiment

Nov 10, 2025 • GlobeNewswire NEUTRAL
Madrigal Presents New Data Demonstrating Rezdiffra® ( resmetirom ) Significantly Improved Multiple Noninvasive Imaging Tests and Biomarkers in Patients with Compensated MASH Cirrhosis
CONSHOHOCKEN, Pa., Nov. 10, 2025 ( GLOBE NEWSWIRE ) -- Madrigal Pharmaceuticals, Inc. ( NASDAQ: MDGL ) , a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis ( MASH ) , today announced positive two-year data from the open-label ...
Nov 05, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Madrigal Q3 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Up
MDGL's wider Q3 loss fails to deter investors, as soaring Rezdiffra sales drive revenues past estimates and lift the stock.
Oct 23, 2025 • Benzinga SOMEWHAT-BULLISH
Why Is Viking Therapeutics Stock Rising Today? - Viking Therapeutics ( NASDAQ:VKTX )
Shares of Viking Therapeutics, Inc. ( NASDAQ:VKTX ) are rising Thursday. The clinical-stage biopharmaceutical company reported third-quarter earnings and provided updates on clinical trials. VKTX stock is racing ahead of the pack. See the full story here.
Oct 22, 2025 • Benzinga SOMEWHAT-BULLISH
Madrigal Pharmaceuticals to Release Third-Quarter 2025 Financial Results and Host Webcast on November 4, 2025 - Madrigal Pharmaceuticals ( NASDAQ:MDGL )
CONSHOHOCKEN, Pa., Oct. 22, 2025 ( GLOBE NEWSWIRE ) -- Madrigal Pharmaceuticals, Inc. ( NASDAQ:MDGL ) , a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis ( MASH ) , announced today that it will release its third-quarter 2025 ...
Oct 20, 2025 • Motley Fool SOMEWHAT-BULLISH
2 Beaten-Down Stocks to Buy and Hold for the Next Decade
That's plenty of time for these drugmakers to move past their challenges.
Oct 07, 2025 • GlobeNewswire BULLISH
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635 ( c ) ( 4 )
CONSHOHOCKEN, Pa., Oct. 07, 2025 ( GLOBE NEWSWIRE ) -- Madrigal Pharmaceuticals, Inc. ( NASDAQ:MDGL ) , a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis ( MASH ) , today announced that it granted equity awards on October 1, ...
Sentiment Snapshot

Average Sentiment Score:

0.317
50 articles with scored sentiment

Overall Sentiment:

Bullish

MDGL Reported Earnings

Aug 05, 2025
Jun 30, 2025 (Pre market)
1.73 Surprise
  • Reported EPS: $-1.90
  • Estimate: $-3.63
  • Whisper: —
  • Surprise %: 47.7%
May 01, 2025
Mar 31, 2025 (Pre market)
2.96 Surprise
  • Reported EPS: $-3.32
  • Estimate: $-6.28
  • Whisper: —
  • Surprise %: 47.1%
Feb 26, 2025
Dec 31, 2024 (Pre market)
1.41 Surprise
  • Reported EPS: $-2.71
  • Estimate: $-4.12
  • Whisper: —
  • Surprise %: 34.3%
Oct 31, 2024
Sep 30, 2024 (Pre market)
1.99 Surprise
  • Reported EPS: $-4.92
  • Estimate: $-6.91
  • Whisper: —
  • Surprise %: 28.8%
Aug 07, 2024
Jun 30, 2024 (Pre market)
0.43 Surprise
  • Reported EPS: $-7.10
  • Estimate: $-7.53
  • Whisper: —
  • Surprise %: 5.7%
May 07, 2024
Mar 31, 2024 (Pre market)
-1.1 Surprise
  • Reported EPS: $-7.38
  • Estimate: $-6.28
  • Whisper: —
  • Surprise %: -17.5%
Feb 28, 2024
Dec 31, 2023 (Pre market)
-0.4 Surprise
  • Reported EPS: $-5.68
  • Estimate: $-5.28
  • Whisper: —
  • Surprise %: -7.6%
Nov 06, 2023
Sep 30, 2023 (Pre market)
-0.41 Surprise
  • Reported EPS: $-5.34
  • Estimate: $-4.93
  • Whisper: —
  • Surprise %: -8.3%
Aug 08, 2023
Jun 30, 2023 (Pre market)
-0.11 Surprise
  • Reported EPS: $-4.69
  • Estimate: $-4.58
  • Whisper: —
  • Surprise %: -2.4%

Financials